The first study conducted in Israel on the effectiveness of a third vaccine showed an increase in antibodies for recipients of heart, liver, kidney and lung transplants. The head of the kidney transplant unit at the Beilinson Transplantation Department, Dr. According to Ruty Rachamimov, 73% of patients who received the third vaccine developed antibodies and their immune systems reacted to the virus, compared to only 35% of those who received the second vaccine.